|
Related Party Transactions (Details) (USD $)
|
1 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Feb. 29, 2012
|
Jun. 30, 2010
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jun. 30, 2013
|
Jun. 30, 2012
|
Jan. 31, 2013
|
Jan. 30, 2013
|
Dec. 31, 2012
|
Sep. 30, 2009
Installment
|
Sep. 21, 2009
|
Feb. 29, 2012
Chromadex Corporation [Member]
|
Feb. 29, 2012
Biozone Pharmaceuticals Inc [Member]
|
Jun. 30, 2012
Biozone Pharmaceuticals Inc [Member]
|
Apr. 30, 2012
Biozone Pharmaceuticals Inc [Member]
|
Sep. 21, 2011
Biozone Pharmaceuticals Inc [Member]
|
May 16, 2011
Biozone Pharmaceuticals Inc [Member]
|
Dec. 31, 2012
Teva [Member]
|
Aug. 31, 2011
Dr. Hsiao [Member]
|
Sep. 21, 2011
Dr. Hsiao [Member]
Aero Pharmaceuticals Inc [Member]
|
Sep. 21, 2011
Dr. Hsiao [Member]
Biozone Pharmaceuticals Inc [Member]
|
Aug. 31, 2011
Mr. Rubin [Member]
|
Sep. 21, 2011
Mr. Rubin [Member]
Biozone Pharmaceuticals Inc [Member]
|
Feb. 29, 2012
Gamma Trust [Member]
|
Feb. 29, 2012
Hsu Gamma [Member]
|
Jun. 30, 2009
Sorrento [Member]
|
Jun. 10, 2009
Sorrento [Member]
|
Nov. 30, 2007
Real Estate Holdings LLC [Member]
sqft
|
Jun. 30, 2013
Real Estate Holdings LLC [Member]
|
Nov. 30, 2010
Fabrus Inc [Member]
|
Aug. 31, 2011
Dr. Frost [Member]
|
Sep. 21, 2011
Dr. Frost [Member]
Aero Pharmaceuticals Inc [Member]
|
Sep. 21, 2011
Dr. Frost [Member]
Biozone Pharmaceuticals Inc [Member]
|
Sep. 21, 2011
Mr. Prego Novo [Member]
Aero Pharmaceuticals Inc [Member]
|
Sep. 21, 2011
Mr. Prego Novo [Member]
Biozone Pharmaceuticals Inc [Member]
|
Jun. 30, 2013
Dr. Lerner [Member]
|
Feb. 29, 2012
Dr. Lerner [Member]
Chromadex Corporation [Member]
|
Dec. 31, 2012
Avi Properties LLC [Member]
sqft
|
Dec. 31, 2012
Avi Properties LLC [Member]
sqft
|
Feb. 29, 2012
Scripps Research Institute [Member]
|
|
| Related Party Transactions (Textual) [Abstract] | ||||||||||||||||||||||||||||||||||||||||
| Period of lease | 5 years | |||||||||||||||||||||||||||||||||||||||
| Square feet of laboratory | 44,000 | 44,000 | ||||||||||||||||||||||||||||||||||||||
| Payments of lease per month | $ 18,000 | |||||||||||||||||||||||||||||||||||||||
| Exceeds consumer price index | 5.00% | |||||||||||||||||||||||||||||||||||||||
| Sale of API to TEVA | 23,821,000 | 10,211,000 | 55,197,000 | 18,988,000 | 100,000 | |||||||||||||||||||||||||||||||||||
| Approximate funding for development of technology | 200,000 | |||||||||||||||||||||||||||||||||||||||
| Period for development of technology | 3 years | |||||||||||||||||||||||||||||||||||||||
| Invested in common shares | 1,000,000 | 2,300,000 | ||||||||||||||||||||||||||||||||||||||
| Beneficially owned held by members | 1.50% | 6.00% | 16.00% | 1.00% | 36.00% | |||||||||||||||||||||||||||||||||||
| Ownership Percentage Held | less than 1% | less than 1% | less than one percent | less than 1% | ||||||||||||||||||||||||||||||||||||
| Sales | 1,700,000 | |||||||||||||||||||||||||||||||||||||||
| Convertible senior notes interest rate | 3.00% | 3.00% | 3.00% | 3.00% | 10.00% | |||||||||||||||||||||||||||||||||||
| Par value | $ 0.20 | |||||||||||||||||||||||||||||||||||||||
| Promissory notes maturity date | Feb. 24, 2014 | |||||||||||||||||||||||||||||||||||||||
| Warrants duration | 10 years | |||||||||||||||||||||||||||||||||||||||
| Warrants to purchase Common shares | 8,500,000 | |||||||||||||||||||||||||||||||||||||||
| Exercise price per share | $ 0.40 | |||||||||||||||||||||||||||||||||||||||
| Issue of common stock / Issue of common stock against acquisition | 339,045,029 | 339,045,029 | 305,560,763 | 13,914 | 8,331,396 | |||||||||||||||||||||||||||||||||||
| Equity Method Investment, Ownership Percentage | 12.00% | 1.70% | 1.00% | 46.00% | 9.20% | 23.00% | 8.20% | |||||||||||||||||||||||||||||||||
| Loan to bzne | 100,000 | 300,000 | ||||||||||||||||||||||||||||||||||||||
| Maximum beneficially owned by members (less than 1%) | 1.00% | 1.00% | 1.00% | |||||||||||||||||||||||||||||||||||||
| Outstanding membership interests on a fully diluted basis | 13.00% | |||||||||||||||||||||||||||||||||||||||
| Investment was part of financing for Fabrus | 2,100,000 | |||||||||||||||||||||||||||||||||||||||
| Ownership percentage held by director | 5.00% | |||||||||||||||||||||||||||||||||||||||
| Outstanding common shares of Sorrento acquired | 0.33 | |||||||||||||||||||||||||||||||||||||||
| Lease space in office building having principal office | 8,300 | |||||||||||||||||||||||||||||||||||||||
| Lease rent per month for first year | 18,000 | |||||||||||||||||||||||||||||||||||||||
| Lease rent per month for fifth year | 24,000 | |||||||||||||||||||||||||||||||||||||||
| Credit for tenant improvements | 30,000 | |||||||||||||||||||||||||||||||||||||||
| Period of lease agreement | 6 months | |||||||||||||||||||||||||||||||||||||||
| Related Party Transactions (Additional Textual) [Abstract] | ||||||||||||||||||||||||||||||||||||||||
| Convertible senior notes | 175,000,000.0 | |||||||||||||||||||||||||||||||||||||||
| Fund for research agreement | 900,000 | |||||||||||||||||||||||||||||||||||||||
| Research agreement maturity period | 5 years | |||||||||||||||||||||||||||||||||||||||
| Research and development agreement amount | 200,000 | |||||||||||||||||||||||||||||||||||||||
| Agreement pursuant to which invested Cocrystal | 2,500,000 | |||||||||||||||||||||||||||||||||||||||
| Number of convertible series preferred stock held from agreement | 1,701,723 | |||||||||||||||||||||||||||||||||||||||
| Previous investment by a group of investor | 5,000,000 | |||||||||||||||||||||||||||||||||||||||
| Additional investment by a group of investor | 5,000,000 | |||||||||||||||||||||||||||||||||||||||
| Number of equal installments payable for additional investment | 2 | |||||||||||||||||||||||||||||||||||||||
| First installment investment | 2,500,000 | |||||||||||||||||||||||||||||||||||||||
| Reimbursement paid to related party for travel | $ 5,000 | $ 65,000 | $ 18,000 | $ 129,000 | ||||||||||||||||||||||||||||||||||||